HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

MLSS

Milestone Scientific Inc. (AMEX)

Healthcare — Medical Instruments & Supplies

Milestone Scientific Inc., a biomedical technology company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical and dental use in the United States, China, and internationally. It operates through Dental and Medical segments. The company provides the Wand, a single use disposable handpiece device for dental procedures that require local anesthetic under the CompuDent and STA Single Tooth Anesthesia System names. It also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection. In addition, the company provides CompuFlo Epidural, a computer-controlled anesthesia system for use in various medical applications. Further, it offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Roseland, New Jersey.

None 2 analysts
$0.35
+$0.03 (+9.38%)
Target: $1.00 (185.7%)
Sign in to add MLSS to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$31.00M
P/E Ratio (TTM)-
Forward P/E-10.01
EPS (TTM)$-0.06
Dividend Yield-
Profit Margin-51.30%
Revenue Growth-3.20%
ROE-135.38%
Debt/Equity43.12
Recommendation None
Analyst Target$1.00
Analysts2
Indexes AMEX

Technical Indicators

RSI (14)40.0
Beta1.02
SMA 20-
SMA 40-
52-Week High$0.73
52-Week Low$0.22
50-Day Avg$0.36
200-Day Avg$0.35
Avg Volume$2.17M
Volume251.8K

Performance Analysis

NEUTRAL

MLSS presents a mixed picture with both positive and negative indicators.

~ Trading at 25% of its 52-week range.
~ RSI at 40.0 is in neutral territory.
~ Price dropped below the 50-day average but remains above the 200-day — possible short-term weakness.
- Revenue declined 3.2% year-over-year.
- Operating at a loss with -51.3% margin.
~ Wall Street consensus is "none" from 2 analysts.
+ Average analyst target of $1.00 implies 185.7% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:20 UTC

Back to Screener Export Report